Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Lancet Oncol
; 18(12): 1600-1609, 2017 12.
Article
in En
| MEDLINE
| ID: mdl-29129441
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Quality of Life
/
Antineoplastic Combined Chemotherapy Protocols
/
Carcinoma, Non-Small-Cell Lung
/
Antibodies, Monoclonal, Humanized
/
B7-H1 Antigen
/
Lung Neoplasms
Type of study:
Clinical_trials
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Lancet Oncol
Journal subject:
NEOPLASIAS
Year:
2017
Type:
Article